Emergency department opioid prescriptions are associated with small increases in hospital admission and subsequent opioid ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

and willingness to continue opioid therapy. A literature search identified more than a dozen published reports on the use of pure opioid antagonists (naloxone, naltrexone, methylnaltrexone ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Ontario's addictions minister says the best way to curb the entry of people to the opioid epidemic is to treat youth mental ...

NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the ...

New research reveals how CBD and THC interact with brain receptors, unlocking potential for safer cannabis-based treatments.

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...

and new opioid agonist therapy prescriptions within 1 year. Secondary outcomes included all-cause acute care utilization and 7-day return ED visits for headache. Among patients who received (n ...